Gilead Sciences (GILD) is in focus after the European Medicines Agency’s Committee for Medicinal Products for Human Use backed the use of Trodelvy plus Keytruda for certain untreated PD-L1 positive metastatic triple-negative breast cancer patients.

The Trodelvy news lands at a time when Gilead Sciences’ share price has a year to date gain of 7.34% and a 1 year total shareholder return of 18.48%, alongside a very strong 5 year total shareholder return of 129.19% that points to sustained momentum rather than a short term spike.

If you are interested in how drug approvals and new indications can reshape opportunities across healthcare, it may be worth reviewing other candidates in the sector through the 41 healthcare AI stocks

Gilead Sciences now appears to be a stronger oncology player after the Trodelvy update, and the share price has already moved. The key question is whether that progress is already reflected in today’s valuation.

Most Popular Narrative: 1.7% Overvalued

The most followed narrative on Gilead Sciences puts fair value at $128.38, slightly below the last close of $130.52, which suggests only a small gap between price and narrative value.

Gilead is transitioning from a “single-franchise HIV company” into a multi-platform biopharma with high-probability growth drivers like lenacapavir and Trodelvy. At the same time, temporary earnings headwinds from heavy investment and M&A could be masking what long-term holders might see as underlying value creation.

Curious what sits behind that fair value for Gilead Sciences. The narrative leans heavily on earnings momentum, margin strength, and a future profit multiple that is usually reserved for faster growing sectors.

Result: Fair Value of $128.38 (OVERVALUED)

However, this Gilead Sciences narrative could be knocked off course if Trodelvy trials disappoint or if recent M&A deals lead to heavier than expected earnings pressure.

Another View On Gilead Sciences’ Valuation

The most popular Gilead Sciences narrative points to a small 1.7% premium to its $128.38 fair value. Yet on simple earnings terms the picture is different. Gilead trades on a P/E of 17.6x while the estimated fair ratio sits much higher at 32.6x.

The stock also screens as slightly expensive against the broader US Biotechs industry at 17x, but it is far cheaper than a 48.9x peer average. For investors, that gap can look like either a valuation cushion or a warning that expectations for peers are far higher. Which story feels more convincing to you.

Next Steps

Given the mixed signals around Gilead Sciences, it makes sense to move quickly and review the numbers in full so you can decide where you stand. To help with that, take a closer look at the balance of risks and rewards highlighted in the 5 key rewards and 1 important warning sign

Looking For More Investment Ideas Beyond Gilead Sciences?

If Gilead Sciences has caught your attention, do not stop there. Use the Simply Wall Street Screener to uncover more stocks that could fit your approach.

• Target resilient compounding potential by checking companies with 84 resilient stocks with low risk scores that score well on stability and business quality.
• Hunt for mispriced opportunities by reviewing 51 high quality undervalued stocks that combine stronger fundamentals with what may be conservative expectations.
• Build income-focused watchlists by scanning 8 dividend fortresses that pair higher yields with balance sheets that support ongoing payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.